The failure or low efficacy of PDE5 inhibitors in DMD patients could have been due to the reason that the PDE5 inhibitors rely on NO and the downstream cGMP production in order to effectively work by inhibiting the breakdown of cGMP. This evidence concerns the gene PDE5A and Duchenne muscular dystrophy.